Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 98.00 | |
2 mg | In stock | $ 138.00 | |
5 mg | In stock | $ 222.00 | |
10 mg | In stock | $ 328.00 | |
25 mg | In stock | $ 553.00 | |
50 mg | In stock | $ 789.00 | |
100 mg | In stock | $ 1,070.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 258.00 |
Description | PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively. |
Targets&IC50 | FGFR1:39.9 nM (IC50), FGFR1:42 nM (Ki), FGFR1 autophosphorylation:622 nM |
Synonyms | PD 161570 |
Molecular Weight | 532.51 |
Formula | C26H35Cl2N7O |
CAS No. | 192705-80-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (56.34 mM), Sonication is recommended.
Ethanol: < 53.25 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PD-161570 192705-80-9 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors PDGFR Src EGFR FGFR Inhibitor Fibroblast growth factor receptor HER1 kinases autophosphorylation PD 161570 inhibit TGF-β Receptor ATP-competitive Epidermal growth factor receptor tyrosine Platelet-derived growth factor receptor disease anti-cancer angiogenesis ErbB-1 PD161570 FGFR1 Transforming growth factor beta receptors cardiovascular anti-proliferation inhibitor